Dazostinag

DB18889InvestigationalSmall molecule

Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors).

Mechanism: Pharmacologically active on Stimulator of interferon genes protein
Curator reviewed
Formula / weight: C₂₁H₂₂F₂N₈O₁₀P₂S₂ · 710.52 g/mol (avg)
Also known as: 7-Deazainosine, [P(R)]-2′-deoxy-2′-fluoro-5′-O-[(R)-hydroxymercaptophosphinyl]-P-thioadenylyl-(3′→5′)-7-fluoro-, cyclic (2′→5′)-nucleotide
Code names: TAK-676

Resolves to

Compound

UNIIW4RT71M1YDCAS2553413-86-6ChEMBLCHEMBL6067966ChEBI759892

Structure

InChIKeySIIGKCBSQKWSLM-RNPBXGGWSA-NSMILES

[H][C@@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](F)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@]([H])([C@@H]1O)[C@@H](O2)N1C=C(F)C2=C1NC=NC2=O)N1C=NC2=C(N)N=CN=C12

Targets

Q86WV6STING1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dazostinag, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account